← All trials
NCT05404516
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2020
- Primary completion
- Aug 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Jun 3, 2022
- Last posted
- Jun 3, 2022
- Enrollment
- 88
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Southern Medical UniversityLead sponsor
- Guangzhou Medical UniversityCollaborator
- Peking UniversityCollaborator
- Southern Medical UniversityCollaborator
- Southern Medical UniversityOverall official - principal investigator
- Southern Medical UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Panyu Central HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.